chevron_leftBack
As of 14 June 2026, Lite Strategy, Inc. has a market cap of $41.27M USD, ranking #31916 globally and #4579 in the United States.
It ranks #2883 in the Healthcare sector, and #999 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$41.27MUSD
Enterprise Value
$32.33MUSD
EBITDA (TTM)
-$16.13MUSD
Net Income (TTM)
-$39.7MUSD
PB Ratio
0.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Justin File
open_in_new
Employees
4
Founded
2000
Website
litestrategy.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.4% | -0.9% | 1.8% | -15% | -42% | -44% |
News
Loading...
LITS Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
LITS
MEI Pharma Inc
ISIN: US55279B3015
Shares Out.:
Shares Outstanding:
34.025M1
Shares Float:
29.883M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.14 USD | |
|
0JW9
MEI Pharma Inc
ISIN: US55279B3015
|
1.15 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
2M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
1M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
874K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
664K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
362K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
285K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
779K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
700K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
665K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
440K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
267K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
263K%
80.96B GBP
|
14.6
|
chevron_leftBack